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Abstract
Changes to the nucleolus, the site of ribosome production, have long been linked to cancer, and mutations in several
ribosomal proteins (RPs) have been associated with an increased risk for cancer in human diseases. Relevantly, a number of
RPs have been shown to bind to MDM2 and inhibit MDM2 E3 ligase activity, leading to p53 stabilization and cell cycle arrest,
thus revealing a RP-Mdm2-p53 signaling pathway that is critical for ribosome biogenesis surveillance. Here, we have
identified RPL37, RPS15, and RPS20 as RPs that can also bind Mdm2 and activate p53. We found that each of the
aforementioned RPs, when ectopically expressed, can stabilize both co-expressed Flag-tagged Mdm2 and HA-tagged p53 in
p53-null cells as well as endogenous p53 in a p53-containing cell line. For each RP, the mechanism of Mdm2 and p53
stabilization appears to be through inhibiting the E3 ubiquitin ligase activity of Mdm2. Interestingly, although they are each
capable of inducing cell death and cell cycle arrest, these RPs differ in the p53 target genes that are regulated upon their
respective introduction into cells. Furthermore, each RP can downregulate MdmX levels but in distinct ways. Thus, RPL37,
RPS15 and RPS20 regulate the Mdm2-p53-MdmX network but employ different mechanisms to do so.
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Introduction
p53 is an important tumor suppressor in cells, and its loss or
mutation has been implicated in at least half of all human cancers
[1]. Molecularly, p53 is a transcription factor that stimulates
expression of numerous target genes in response to stress [2].
Levels of p53 are tightly regulated by Mdm2, a RING-type E3
ubiquitin ligase that binds to the N-terminal transactivation
domain of p53 via sequences within its own N-terminal region.
Mdm2 both inhibits p53 transactivation of its target genes and
ubiquitinates lysines within the p53 C-terminus. Mdm2-mediated
ubiquitination targets p53 for nuclear export and degradation by
the proteasome [3]. p53 activity is also regulated by MdmX, a
homolog of Mdm2 that also contains a N-terminal p53-binding
domain and a C-terminal RING domain [4]. Just as with Mdm2,
binding of the MdmX N-terminus to p53 inhibits its transactiva-
tion activity, but in the case of MdmX, its RING domain does not
function to ubiquitinate p53. Rather, MdmX forms hetero-
oligomers with Mdm2 in cells and likely directs Mdm2 RING
activity towards p53 ubiquitination and away from Mdm2 auto-
ubiquitination [5,6].
Upon some forms of cellular stress, MdmX is degraded, thus
releasing p53 from inhibition [7,8], and Mdm2 and p53 are
modified so that Mdm2 cannot bind to p53 and target it for
degradation. Both mechanisms allow for a buildup of active p53
and arrest of the cell cycle or, depending on the extent of the
damage or cellular context, apoptosis. The accumulation of p53
also stimulates expression of Mdm2, thus completing an important
negative feedback loop whereby p53 is eventually degraded once
the stress has passed [9]. It is noteworthy that, unlike p53, Mdm2
and MdmX are only rarely mutated in human cancers; rather,
they are sometimes amplified [10]. The rare exceptions that have
been identified for Mdm2 consist of a few missense mutations
located within the central acidic region, which coincidentally is the
same region that interacts with various ribosomal proteins (RPs).
While the nucleolus had already been linked to p53 by multiple
lines of evidence [11], the first report to directly link a ribosomal
protein (RP) to p53 identified a physical interaction between
Mdm2, p53, 5S rRNA, and RPL5 [12]. The significance of this
interaction was unclear until it was published that RPL11 can also
bind Mdm2, and overexpressing this RP allowed for the inhibition
of the ubiquitination and degradation of p53 [13,14]. RPL11 was
also shown to stimulate the Mdm2-mediated ubiquitination and
degradation of MdmX [15].
The interaction between RPL11 and Mdm2 is not a unique
phenomenon since it was then shown that p53 can be stabilized in
an Mdm2-dependent manner by ectopic expression of RPL5,
RPL23, RPS7, RPS14, RPS25, as well as RPS27, RPS27A, and
RPS27L. These RPs all bind to the central region of Mdm2 and
inhibit its E3 ubiquitin ligase activity, leading to the activation of
p53 [16,13,17,18,19,20,21,22,23,24]. Although knockdown of
these RPs by siRNA have varying impacts on p53 protein levels
in the absence of stress, they attenuate the induction of p53 when
ribosomal stress is introduced to cells. For example, siRPL5 [16]
and siRPL11 [13] reduce levels of p53 both basally and in
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response to stress, while siRPL23 and siRPS14 increase levels of
basal p53 but attenuate the p53 response to ribosomal stress
[17,21]. Furthermore, RPL5 and RPL11 were recently shown to
accumulate in ribosomal-free fractions in response to actinomycin
D (ActD)-induced ribosomal stress [25]. Interestingly, the few
tumor-derived missense mutants of Mdm2 that have been
identified impair binding to RPL5 and RPL11 while maintaining
their interaction with p53 [26]. Furthermore, a mouse bearing one
of these mutations (Mdm2-C305F) was shown to have significantly
accelerated tumor development in an Em-Myc mouse model [27].
Another ribosomal protein, RPL26, was also shown to be a
positive regulator of p53, but by more complex mechanisms. After
irradiation of cells, RPL26 binds to both the 59 UTR and 39 UTR
of p53 mRNA and stimulates its translation [28,29], while under
non-stressed conditions, RPL26 is targeted for degradation by
Mdm2 and is inhibited from interacting with p53 mRNA by
Mdm2 [30]. More recently, RPL26 was shown to stabilize p53
through inhibiting the ubiquitin ligase activity of Mdm2, similar to
the RPs mentioned above [31].
Interestingly, the role of RPs in regulating p53 signaling through
Mdm2 interaction is not limited to ribosomal stress. It was shown
that stress-induced p53 stabilization was attenuated by the various
DNA damage agents after RPS7 or RPL11 ablation [20]. Also,
another RP from the 40S small subunit, RPS3, was shown to
interact with both p53 and Mdm2, and knockdown of RPS3 by
siRNA led to an attenuation of p53 upregulation in response to
oxidative stress [32].
Our experiments identify three new RPs, RPL37, RPS15, and
RPS20, that bind to and regulate Mdm2 and MdmX, and thereby
p53. While they each appear to function similarly to many of the
other RPs described above in their regulation of Mdm2, we noted
interesting differences among them in the modes by which they
interact with Mdm2, in their respective abilities to regulate p53
target gene expression, and how they regulate MdmX protein
levels. Such differences might eventually provide a clue as to why




Flag-Mdm2 (full length and deletion constructs), HA-MdmX,
HA-p53, HA-ubiquitin, and GFP plasmids were described
previously [20]. For Myc-RPs, total RNA was extracted from
HEK293 cells (RNeasy Mini Kit, Qiagen) and a cDNA library was
made by reverse-transcription (QuantiTect Reverse Transcription
Kit, Qiagen). RPL37, RPS15, and RPS20 fragments were
amplified from the cDNA library by PCR and cloned into the
pcDNA3-Myc vector using the following primers: 59-AAGGATC-
CAATGACGAAGGGAACGTCAT-39 and 59-CCTCTAGAT-
TAAGATGAACTGGATGCT-39 for RPL37 forward and re-
verse, respectively; 59-AAGGATCCAATGGCAGAAGTAGA-
GCAGA-39 and 59-CCGAATTCTTACTTGAGAGGGATGA-
AG-39 for RPS15 forward and reverse, respectively; and 59-
CCGGATCCAATGGCTTTTAAGGATACCG-39 and 59-CC-
CTCGAGTTAAGCATCTGCAATGGTG-39 for RPS20 for-
ward and reverse, respectively. DNA sequences were confirmed
using the NCBI reference database. siRNA sequences (Table S1)
were obtained commercially (Qiagen); siRPs were pre-designed by
the manufacturer while control siRNA (siRNA versus luciferase;
siLuc) was previously described [54].
Cells Culture and Transfection
U2OS osteosarcoma, SJSA osteosarcoma, and H1299 lung
carcinoma cell lines were described previously [20]. Cells were
seeded in 35 mM culture plates prior to transfection, except where
indicated. DNA transfections were performed for 24 hours with
Lipofectamine 2000 (Invitrogen) or FuGENE6 (Promega) accord-
ing to the manufacturer’s instructions; siRNA transfections were
performed for 72 hours with DharmFECT1 (Thermo Scientific)
according to the manufacturer’s instructions. All DNA transfec-
tions were balanced with pCDNA3-Myc to ensure equal amounts
of total DNA were used, and all siRNA transfections were
balanced with siLuciferase (Qiagen). Cells were harvested 24 hours
after DNA transfection or 72 hours after siRNA transfection.
Frozen cell pellets were stored at 280uC until processed for RNA
or protein analyses. In the case of cell cycle analyses, cells were
processed immediately upon harvesting.
Antibodies and Immunoblotting
Transfected cells were lysed with 100 ml Lysis Buffer (25 mM
Tris-Hcl pH 7.5, 137 mM NaCl, 2.7 mM KCl, and 0.5% Igepal
CA-630 supplemented with 50 nM PMSF and inhibitor cocktail
containing 100 uM Benzamidine, 300 ug/uL Leupeptin,
100 mg/mL Bacitracin, and 1 mg/mL a2-macroglobulin), and
cell lysates were cleared by spinning at 4,000 rpm for 10 minutes.
Protein concentrations were determined by Bradford assay, and
equivalent amounts of each transfected and clarified cell lysate was
loaded onto a polyacrylamide gel and separated using constant
voltage. Proteins were transferred onto nitrocellulose membranes
(Bio-Rad), blocked, and probed using the following antibodies:
anti-actin (A2066, Sigma); anti-Flag (M2, Sigma); anti-GFP (B2,
Santa Cruz Biotechnology); anti-HA (16B12, Covance); anti-
Mdm2 (a mixture of 3G5, 4B11, and 5B10 hybridomas); anti-
MdmX (A300-287A, Bethyl Laboratories); anti-Myc (9E10, Santa
Cruz Biotechnology or C3956, Sigma); anti-p21 (C19, Santa Cruz
Biotechnology); anti-p53 (a mixture of 1801 and D01 hybridomas);
anti-RPL37 (AP95656, Abgent); anti-RPS15 (AP6914a, Abgent);
anti-RPS20 (ab74700, Abcam). Membranes were washed with
PBS supplemented with 0.1% Tween 20 prior to the addition of
secondary antibodies. In some cases, a goat anti-mouse or goat
anti-rabbit conjugated to horseradish-peroxidase (Sigma) was
used, and membranes were visualized using ECL (GE Healthcare).
In other cases, fluorescent green goat anti-mouse (IRDye 800CW,
LI-COR Biosciences) and fluorescent red donkey anti-rabbit
(IRDye 680LT, LI-COR Biosciences) secondary antibodies were
used in conjunction with the Odyssey Imaging System (LI-COR
Biosciences).
Immunoprecipitations
H1299 cells were transfected with Myc-RPs, various Flag-
Mdm2 constructs, or HA-MdmX as indicated. Equivalent
amounts of each clarified cell lysate was subjected to immunopre-
cipitation with 1 mg of a monoclonal Myc antibody (9E10, Santa
Cruz Biotechnology). For co-immunoprecipitation of endogenous
proteins, confluent SJSA cells were lysed and cleared as described.
SJSA cell lysates were pre-cleared with Protein G Sepharose beads
(GE Healthcare) before immunoprecipitating with 1 mg of normal
rabbit IgG (IB140, Sigma) or 1 mg of a monoclonal Mdm2
antibody (N20, Santa Cruz Biotechnology). Pre-blocked Protein G
Sepharose beads were added to cell lysates for 45 minutes, and
unbound proteins were removed by washing with Lysis Buffer.
Samples were resuspended in Lysis Buffer and Protein Sample
Buffer prior to boiling at 95uC for 10 minutes.
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Ubiquitination Assays
H1299 cells were transfected with HA-Ubiquitin, p53, Flag-
Mdm2, or Myc-RPs as indicated. 18 hours after transfection,
H1299 cells were treated with 25 mM MG132 (Calbiochem) for 6
hours. Equivalent amounts of clarified cell lysates were immuno-
precipitated with 1 mg of anti-p53 (in the case of Mdm2-mediated
ubiquitination of transfected p53) or 1.9 mg of anti-Flag (in the
case of auto-ubiquitination of transfected Flag-Mdm2) followed by
Western blot using anti-HA antibody to detect ubiquitinated p53
or Mdm2 species.
Cycloheximide Assay
U2OS cells were transfected with empty vector (pcDNA3-Myc)
or the indicated Myc-tagged RP as indicated. Approximately 23
hours after transfection, cells were treated with 100 mg/mL
cycloheximide (Sigma) and harvested at the indicated time points.
Cell lysates were subjected to immunoblotting with anti-p53 and
anti-actin antibodies, and band intensities were quantified using
Odyssey software (LI-COR Biosciences). After normalizing the
p53 band intensities to actin, the protein half-life of p53 was
calculated using a one-phase exponential decay model (GraphPad
Prism).
Figure 1. RPL37, RPS15, and RPS20 interact with Mdm2. (a–c) Association of ectopically expressed RPs and Mdm2. H1299 cells were
transfected with Flag-Mdm2 (1.2 mg), Myc-RP (1.2 mg), or both. (0.1 mg GFP was added as a control for transfection efficiency.) Cells were then lysed
and subjected to immunoprecipitation and immunoblotting (IP) with the indicated antibodies as described. (d) Association of endogenously
expressed RPs and Mdm2. SJSA cell lysates were subjected to immunoprecipitation with a-Mdm2, and co-immunoprecipitation of each RP was
detected by immunoblotting with the relevant antibody. Since RPL37 and RPS20 run very close together, 2 independent blots are shown. In the left
panel, RPL37 was blotted first and RPS15 second; in the right panel, RPS15 was blotted first and RPS20 was blotted second. Immunoblots in the right
panel are taken from the same gel. (e) Mapping sites of interaction between RPs and Mdm2. H1299 cells were transfected with each Myc-RP (1.2 mg)
and various amounts of each Flag-Mdm2 construct (full length; truncation 1–154; truncation 1–220; deletion 222–272; deletion 222–340; deletion
340–437; truncation 436–482) as shown in Figure S2. Myc-RPs were immunoprecipitated with a-Myc, and co-immunoprecipitation of each RP and
each Mdm2 construct was assayed by immunoblotting with a-Myc and a-Flag. Shown here is the summary of these binding assays (individual
immunoblots are shown in Figure S2). Mdm2 protein landmarks are depicted above, and regions bound by each indicated RPs is depicted below.
doi:10.1371/journal.pone.0068667.g001
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Quantitative RT-PCR
U2OS cells were transfected with Myc-RP as indicated. Total
RNA was extracted from transfected cell pellets using the RNeasy
Mini Kit (Qiagen), and cDNA was synthesized using the
QuantiTect Reverse Transcription Kit (Qiagen). Expression of
each gene was determined in triplicate using SYBR Green
(Applied Biosystems) on a StepOnePlus Real-Time PCR machine
(Applied Biosystems). Each sample was normalized using GAPDH
primers, and relative gene expressions were determined using the
DDCt method. Primer sequences (Table S2) were designed using
Primer Express software (Applied Biosystems) and validated for
efficiency and specificity prior to the start of experimentation.
Cell Cycle Analysis
U2OS cells were transfected with Myc-RP as indicated.
Twenty-four hour after transfection, transfected cells were fixed
and stained with propidium iodide (PI) as previously described
[54] and analyzed using a FACS Calibur machine (BD
Biosciences). Cell cycle distribution was determined using the
ModFit LT program (Verity House Software), and sub-G1 content
was determined using CellQuest software (BD Biosciences).
Results
RPL37, RPS15, and RPS20 Interact with Mdm2
A yeast two-hybrid screen using Mdm2 as bait [20] identified
several RPs as potential interactors with Mdm2. Among the
candidate Mdm2-interacting RPs identified were RPL11 [13,14],
RPL26 [28], RPS7 [19,20], and RPS27A [24] which have been
confirmed in published studies as bona fide interactors with Mdm2
and regulators of p53. Therefore, we sought to validate the
additional RPs identified in the yeast two-hybrid screen by testing
the interaction of RPL37, RPS15, and RPS20 with Mdm2 in
mammalian cells. RPL37, RPS15, and RPS20 were cloned into a
mammalian expression vector and transfected into H1299 lung
carcinoma cells alongside Mdm2. When the transfected RPs were
immunoprecipitated from the cell lysates, we found Mdm2 could
associate with each of these RPs (Figures 1a–1c). Significantly, the
H1299 cell line is p53-null, indicating that the interactions of these
three RPs with Mdm2 is independent of p53. The presence of p53
did not abrogate the interactions, however, as a similar result was
observed with transfected RPs and Mdm2 in the p53-containing
U2OS osteosarcoma cell line (Figure S1). We also confirmed an
interaction between the endogenously expressed RPs and Mdm2
in the SJSA osteosarcoma cell line that harbors wild-type p53
(Figure 1d).
We next sought to map the regions of Mdm2 that are
responsible for interacting with these proteins. Other RPs
(RPL5, RPL11, RPL23, RPS7, and RPS14) have each been
shown to bind to the central acidic region or central Zinc finger
region of Mdm2 [16,13,17,20,21]. Using a panel of Mdm2
deletion constructs, we found that RPL37, RPS15, and RPS20 can
also bind to the central Zinc finger region of Mdm2, between
amino acids 273–339 (Figure 1e). A Mdm2 variant lacking
residues 340–437 bound better than full–length Mdm2 to each of
the RPs, suggesting the region spanning amino acids 340-437
inhibits their interaction (Figure S2). Interestingly as well, RPS15
and RPS20 but not RPL37 can also interact (albeit weakly) with
the N-terminal 220 amino acids of Mdm2, where the p53-
interacting domain lies, as well as the C-terminus of Mdm2, where
the RING domain lies (Figure S2). This suggests either that the
tertiary structure of MDM2 augments its interaction with these
two RPs or that they possess additional binding surfaces for
Mdm2.
RPL37, RPS15, and RPS20 Stabilize Mdm2 and p53 by
Inhibiting Mdm2 Ubiquitin Ligase Activity
To determine the functional consequence of the physical
interaction between RPL37, RPS15, and RPS20 and Mdm2,
H1299 cells were transfected with a constant quantity of Flag-
Mdm2 and increasing amounts of each Myc-RP. Levels of Flag-
Mdm2 were increased by co-transfected RPs in a dose-dependent
manner (Figure 2a). A similar stabilization of Flag-Mdm2 by these
three RPs was seen when cells that were co-transfected Mdm2 and
RPs were visualized by immuofluoresent microscopy (Figure S3).
As Mdm2 may control its own degradation through its ubiquitin
ligase activity, we introduced HA-tagged ubiquitin into H1299
cells and confirmed that each RP can inhibit Mdm2 auto-
ubiquitination (Figures 2b–2d).
We further examined whether the ability of these RPs to
regulate Mdm2 levels had an impact on p53 levels. As shown in
Figure 3a, when each RP was co-expressed in U2OS cells along
with Flag-Mdm2 and HA-p53, they were able to inhibit Mdm2-
mediated degradation of p53. More significantly, levels of
endogenous Mdm2 and p53 in U2OS cells were elevated following
expression of each RP in a dose-dependent manner (Figures 3b–
3d). Note as well that levels of p21 protein were increased along
with p53.
Consistent with the above observations, cycloheximide chase
assays revealed that the half-life of p53 was dramatically increased
by the addition of each RP (Figures 4a–4c). RPL37 was able to
roughly double the half-life of p53, while RPS15 and RPS20 were
able to extend the half-life of p53 by more than 4-fold. The
underlying mechanism responsible for the ability of each RP to
inhibit Mdm2-mediated degradation of p53 was obtained from
experiments showing that that each RP inhibits Mdm2-mediated
ubiquitination of p53 in vivo (Figures 4d–4f). Together, these data
suggest that ectopically expressed RPL37, RPS15, and RPS20
regulate Mdm2 and p53 levels by binding to Mdm2 and inhibiting
its E3 ubiquitin ligase activity towards itself and p53.
RPL37, RPS15, and RPS20 Increase Cell Death and Cell
Cycle Arrest
To examine the physiological consequence of the ectopic
expression of RPL37, RPS15, or RPS20, we examined the cell
cycle profiles of U2OS cells transfected with each of the RPs by
FACS analysis. We found the overexpression of each of the three
RPs was able to modestly, but significantly, increase the sub-G1
content of transfected U2OS cells in a dose-dependent manner,
indicating that they can facilitate programmed cell death in this
setting (Figure 5a). Surprisingly, RPL37 expression had only a
negligible impact on the proportion of cells in G1 phase even
though p21 protein levels were increased (Figure 3b). Instead, we
found that RPL37 mediated a significant G2 arrest and a mild
drop in S phase (Figures 5b–5d). In the case of RPS15, a
significant G2 arrest was seen with a mild drop in G1 phase, and
the G2 arrest mediated by RPS20 correlated with modest drops in
both G1 and S phases (Figures 5b–5d). p21 has previously been
shown to mediate G2 arrest in response to gamma irradiation
[33], but it remains possible that a different target (or targets) of
p53 is regulated by the three RPs to cause cells to arrest in G2.
Stabilization of p53 by RPL37, RPS15, and RPS20 Leads to
Upregulation of Specific p53 Targets
Upon treatment of cells with agents such as actinomycin D
(ActD) or 5-fluorouracil (5-FU) that cause ribosomal stress, p53
becomes stabilized and can activate its myriad downstream target
genes. Since it is possible that one of the modes by which such
p53 Regulation by Ribosomal Proteins L37, S15, S20
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ribosomal stress activates p53 is through freed RPs arising from
nucleolar disruption, we sought to determine how the three RPs
that we characterized in this study affect the transcriptional
activity of p53. As a transcription factor, p53 increases expression
of genes which can participate in cell cycle arrest (such as p21) or
apoptosis (such as Bax, Noxa, and Puma) or both (such as miR-
34a, a micro RNA target of p53 [34] that indirectly causes an
increase in p21 and Puma expression by inhibiting Sirt1 [35]). p53
can also regulate metabolic flux through targets such as TIGAR
[36] and can regulate itself through targets such as Mdm2 [37]
and Ccng1 [38,39]. As mentioned above, the ability of certain RPs
to stabilize p53 with an ensuing cell outcome has been well
documented. With few exceptions [40,41], the impact of RPs on
the ability of p53 to regulate its various target genes has not been
Figure 2. RPL37, RPS15, and RPS20 stabilize Mdm2. (a) Stabilization of ectopically expressed Mdm2 by RPs. H1299 cells were transfected with
Flag-Mdm2 (1.2 mg) and Myc-RP (1.0–3.0 mg). (GFP was added as a control for transfection efficiency.) Mdm2 and RP levels were detected by
immunoblotting with a-Myc and a-Flag. (b–d) Inhibition of Mdm2 auto-ubiquitination by RPs. H1299 cells were seeded in 60 mM tissue culture plates
and transfected with HA-Ubiquitin (3.0 mg), Flag-Mdm2 (3.0 mg), and Myc-RP (8.0 mg for RPL37; 9.0 mg for RPS15 and RPS20). MG132 was added for 6
hours, and ubiquitinated Mdm2 species were assayed by immunoprecipitating with a-Flag and immunoblotting with a-HA. The asterisk indicates a
non-specific band that runs below Flag-Mdm2. Inputs and IPs were run on separate gels.
doi:10.1371/journal.pone.0068667.g002
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examined. We therefore checked a few select but key p53
responsive genes for an in vivo response to ectopic expression of
RPL37, RPS15, and RPS20.
Interestingly, not only did different p53 target genes vary in
their response to ectopic RP expression, the 3 RPs differed among
themselves in their ability to regulate expression of some of these
genes. Consistent with our observation that RPL37, RPS15, and
RPS20 could cause a dose-dependent increase in p21 protein
levels (Figures 3b-3d), p21 mRNA accumulation was also
increased when each of the 3 RPs were expressed (Figure 6a).
Expression of each RP also led to increased Puma mRNA levels
(Figure 6b). In other cases, p53 target genes were induced by only
a subset of the three RPs. Specifically, RPS15 and RPS20, but not
RPL37, were able to increase mRNA levels of Mdm2 (Figure 6b)
and miR-34a (Figure 6d) in a dose-dependent manner. Finally,
expression of a third category of p53 targets (Ccng1, Bax, Noxa
and Tigar) was not affected by these RPs to a significant degree
(Figure S4a–d).
Downregulation of MdmX Protein Levels by RPL37,
RPS15, and RPS20
To further investigate possible differences in the in vivo functions
of RPL37, RPS15, and RPS20, we asked whether they may play a
role in the regulation of MdmX. RPL11 was previously shown to
indirectly downregulate MdmX levels in a Mdm2-ubiquitination
dependent manner [15], but the ability of other RPs to regulate
MdmX has not been explored. When the RPs were immunopre-
Figure 3. RPL37, RPS15, and RPS20 increase levels of p53. (a) Stabilization of ectopically expressed p53 by RPs. U2OS cells were transfected
with Flag-Mdm2 (1.2 mg), HA-p53 (0.3 mg), and Myc-RP (1.0–3.0 mg). (GFP was added as a control for transfection efficiency.) Ectopic Mdm2, p53, and
RP levels were detected by immunoblotting with a-Flag, a-HA and a-Myc. (b–d) Stabilization of endogenously expressed p53 by RPs. U2OS cells were
transfected with increasing amounts of Myc-RP (0–3.0 mg), and endogenous proteins were detected by immunoblotting with the indicated
antibodies.
doi:10.1371/journal.pone.0068667.g003
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Figure 4. RPL37, RPS15, and RPS20 stabilize p53 protein. (a–c) Increase in half-life of p53 by RPs. U2OS cells were seeded in 35 mM tissue
culture plates and transfected with empty vector (3.0 mg) or Myc-RP (3.0 mg). Approximately 22 hours after the initial transfection, 100 mg/mL
cycloheximide was added to the culture medium and cells were harvested at the indicated timepoints. (d–f) Inhibition of Mdm2-mediated
ubiquitination of p53 by RPs. H1299 cells were seeded in 60 mM tissue culture plates and transfected with HA-Ubiquitin (3.0 mg), p53 (0.75 mg), Flag-
Mdm2 (7.5 mg), and Myc-RP (9.0 mg). MG132 was added for 6 hours, and ubiquitinated p53 species were assayed by immunoprecipitating with a-p53
and immunoblotting with a-HA. Inputs and IPs were run on separate gels.
doi:10.1371/journal.pone.0068667.g004
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cipitated from H1299 cell lysates transfected with individual Myc-
tagged RPs and HA-tagged MdmX, RPS15 and RPS20 but not
RPL37 co-immunoprecipitated with MdmX (Figures 7a–7c). It is
interesting that RPS15 and RPS20 were the RPs that exhibited
weak interactions with the N-terminal and RING domains of
Mdm2, while RPL37 did not interact with those regions of Mdm2
(Figure 1e, Figures S2). The N-terminal domains of Mdm2 and
MdmX share the highest sequence homology with each other [4],
and the RING domains of Mdm2 and MdmX are the sites of
interaction between the two Mdm proteins [42,43].
Despite the absence of a physical interaction between RPL37
and MdmX proteins, ectopic expression of RPL37 was able to
cause a dose-dependent drop in MdmX levels (Figure 7d), as were
RPS15 and RPS20 (Figures 7e–7f). As a possible explanation for
the apparent contradiction between RPL37 regulating MdmX
protein levels without binding to the protein, levels of MdmX
mRNA were assayed. RPL37, but not RPS15 and RPS20, was
able to cause a reduction in MdmX mRNA levels (Figure 7g),
suggesting it has a different mechanism for regulating MdmX
protein levels than the other RPs.
Knockdown of RPL37, RPS15, and RPS20 by siRNA
Increase Levels of p53 and p21 but Decrease Levels of
MdmX
As mentioned in the Introduction, siRNA-mediated depletion of
some RPs that were shown to interact with Mdm2 is correlated
with a decrease in p53 levels, while reduction of other RPs by
siRNA was shown to perturb ribosomal biogenesis and lead to
activation of p53. RPL37 was previously reported to fall in the
latter category of RPs, as a siRNA targeting RPL37 was shown to
activate p53 [44]. Indeed, using a different siRNA sequence to
deplete RPL37 also led to upregulation of p53 and p21 (Figure 8a).
Similarly, siRNA mediated ablation of RPS15 and RPS20 led to
upregulation of p53 and p21 (Figures 8b–8c).
The effect of siRNA-mediated knockdown of RPs on MdmX
other than siRPL11 [15] has not been widely reported. Here we
found that siRPL37, siRPS15, and siRPS20 could also lead to a
decrease in MdmX protein levels. Given the uniformity of this
response, it is possible that, just like stressing cells with low doses of
Figure 5. Ectopic expression of RPL37, RPS15, and RPS20 increases cell death and G2 arrest. (a–d) Increase in Sub-G1 and G2 by RPs.
U2OS cells were seeded in 60 mM tissue culture plates and transfected with increasing amounts of Myc-RP (0–7.5 mg). Cell cycle analysis was carried
out as described and normalized to the 0 mg Myc-RP control. The average of at least 3 independent experiments is plotted, and asterisks indicate
where significant changes were observed in the cell cycle profile (* = p,0.05; ** = p,0.01; n .3).
doi:10.1371/journal.pone.0068667.g005
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ActD leads to MdmX degradation, depleting RPs may introduce
ribosomal stress that lead cells to decrease levels of MdmX protein.
Discussion
The three ribosomal proteins that are the focus of this paper
have each been implicated in activating p53 or inducing cancer.
Ablation of RPL37 by siRNA was shown to disrupt ribosomal
biogenesis and upregulate p53 [44], and also lead to the
upregulation of a variety of p53 targets [40]. A case of
Diamond-Blackfan anemia, a heritable human disorder charac-
terized by a predisposition to cancer, was identified where RPS15
had been mutated [45]. In a genetic screen, RPS15 was identified
as a haploinsufficient tumor suppressor in zebrafish [46]. Similarly,
a mouse carrying a mutation in RPS20 was found to have
activated p53 that leads to both anemia (due to an increase in
apoptosis of erythrocytes) and darkened skin (due to an increase in
the proliferation of melanocytes) [47]. Here we show that ablation
of these three RPs by siRNA can lead to increased levels of p53, as
can overexpression.
The experiments in this study have relied extensively on analysis
of ectopically expressed ribosomal proteins. As such, they have
both confirmed and extended observations made with other RPs,
which, when similarly introduced into cells, lead to inhibition of
Mdm2 activity and thereby stabilization of both p53 and Mdm2.
While arguments that ectopically expressed proteins may be
present at levels that are non-physiologically high are certainly
valid in the case of many proteins, ribosomal proteins themselves
are normally among the most abundant proteins in the cell, and
the amount that we are adding to the cellular pool is therefore
unlikely to make a significant difference. Rather what we think we
are accomplishing in our experiments is mimicking the situation
that occurs upon ribosomal stress, which features nucleolar
disruption and dispersal of free ribosomal proteins. Although
some ribosomal proteins are rapidly degraded after some forms of
ribosomal stress, others (RPL5 and RPL11) are stable [25]. To
gain more insight into the likely roles of these proteins, it might be
appropriate to further examine the consequences of depletion of
these RPs on the p53 pathway in future studies. However, there
are arguments that such approaches might not be that informative.
Figure 6. Ectopic expression of RPL37, RPS15, and RPS20 induces specific p53 target genes. (a–d) Increase in some p53 target genes by
RPs. U2OS cells were seeded in 60 mM tissue culture plates and transfected with increasing amounts of Myc-RP (0–7.5 mg). Relative expression of
each gene was determined in triplicate by quantitative RT-PCR and normalized to GAPDH. A representative experiment is plotted, and significant
changes in mRNA levels were calculated using student’s t-test (* = p,0.05; ** = p,0.01; n .3).
doi:10.1371/journal.pone.0068667.g006
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In many cases, knockdown of RPs induces rather than suppresses
activation of p53 due to the relationship between RPL11 and
other RPs first noted by Thomas and colleagues [48] and later by
Dai and colleagues [49], and siRPL37, siRPS15, and siRPS20
may function similarly. The former found that disruption of 40S
ribosome biogenesis mediated by siRPS6 causes arrest of the cell
cycle in an RPL11-dependent manner, and the latter found that
perturbation of 60S ribosome biogenesis mediated by siRPL29 or
siRPL30 results in a similar outcome. A second argument is that
siRNAs targeting even the same RP (e.g. RPS7) seem to provide
different results in different reports (e.g. compare [19] and [20]
versus [50] and [25]). Therefore, we feel that the results in this
paper provide new information about the relationship between
RPs and p53 as discussed below.
Figure 7. RPL37, RPS15, and RPS20 bind to and regulate MdmX levels. (a–c) Association of RPs and MdmX. H1299 cells were transfected
with HA-MdmX (0.5 mg), Myc-RP (1.2 mg), or both. (GFP was added as a control for transfection efficiency.) Ectopic MdmX and RP levels were detected
by immunoblotting with a-MdmX and a-Myc. Inputs and IPs were run on separate gels. (d–f) Decrease in MdmX protein by RPs. U2OS cells were
transfected with increasing amounts of Myc-RP (0–2.0 mg). Endogenous proteins were detected by immunoblotting with the indicated antibodies. (g)
Decrease in MdmX mRNA by RPL37. U2OS cells were seeded in 60 mM tissue culture plates and transfected with Myc-RP (0–5.0 mg). Relative
expression of MdmX mRNA was determined by quantitative RT-PCR and normalized to GAPDH. A representative experiment is plotted, and
significant changes in mRNA levels were calculated using student’s t-test (* = p,0.05; ** = p,0.01; n .3).
doi:10.1371/journal.pone.0068667.g007
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Increasing numbers of RPs have been shown to contribute to
p53 stress response. It was recently hypothesized that those RPs
can be classified as ‘‘detector’’ RPs or ‘‘effector’’ RPs [44,51].
Effector RPs, such as RPL11, can inhibit Mdm2-mediated
ubiquitination and degradation of p53 when overexpressed, and
most of those have also been shown to attenuate the response to
stress when knocked down by siRNA. On the other hand, detector
RPs, such as RPL7A, RPL24, RPL29, RPL30, RPL37, RPS6,
RPS23, and RPS9 [52,49,44,48,53], have an effect on p53 levels
only when reduced by siRNA – they do not co-immunoprecipitate
with Mdm2 and have no effect on p53 levels when they are
overexpressed. These RPs appear to contribute to the p53 stress
response by triggering an increase in levels or activity of RPL11
[49], and are thus indirect regulators of p53. Prior evidence
suggests RPL37, RPS15, and RPS20 are detector RPs, as
knockdown of RPL37 by siRNA [44] or mutation of RPS15
[46] and RPS20 leads to p53 activation or tumorigenicity [47].
Nevertheless, our experiments suggest that they can also be seen as
effector-type regulators of p53. We observed that RPL37, RPS15,
and RPS20 can bind Mdm2, inhibit degradation of Mdm2 and
p53, cause apoptosis and cell cycle arrest in G2, upregulate p21
and Puma mRNAs, and downregulate MdmX protein levels.
Intriguingly, stable cell lines overexpressing GFP-RPL37 can
arrest cells in G1 phase [44]. The discrepancy between our results
and theirs may due to the fact that the experiment we carried out
used transient transfection while they were using cell lines
harboring a GFP-tagged protein.
Currently, it is quite mysterious why so many RPs play
seemingly redundant roles in regulating levels of p53. One
conclusion to draw from the surfeit of RPs that can regulate the
Mdm2-p53 axis is that ribosomal biogenesis is a hugely complex
process and responding to interruptions in it is vitally important. It
is possible that perturbation to the beginning, middle, or ending
stages of ribosomal biogenesis generate specific stress signals that
activate different RPs that go on to signal to the Mdm2-p53 axis.
Also, different RPs may mediate p53 activation with different
kinetics upon stress stimuli to ensure a proper cellular response.
Finally, different RPs may target Mdm2 or p53 in different ways,
such as inhibiting degradation of p53 protein or stimulating
translation of p53 mRNA, as RPL26 does [28].
As each RP is studied in more detail, it is possible that more
differences will appear in the downstream consequences of their
ability to activate p53. For example, we observed RPL37, RPS15,
and RPS20 could stimulate G2 arrest, while RPL23, RPS7 and
RPS25 have been shown to stimulate G1 arrest [17,20,22].
Additionally, we have shown that RPL37, RPS15, and RPS20
differ from each other in their impacts on various p53 targets. A
recent study showed knockdown of RPL37 in mouse embryonic
stem cells or induced pluripotent stem cells led to the upregulation
of multiple p53 targets including p21, Mdm2, Pidd, Puma, Noxa,
Figure 8. Knockdown of RPL37, RPS15, and RPS20 activate p53. (a–c) Increase in p53 and p21 by RPs. U2OS cells were transfected with siRNA
targeting RPL37, RPS15, or RPS20 as indicated (0 mM, 50 mM, 100 mM, 200 mM). Cells were harvested and lysates were subjected to immunoblotting
for Mdm2, MdmX, p53, p21, and the indicated RPs with the relevant antibodies. Immunoblots in panel (c) are taken from the same gel.
doi:10.1371/journal.pone.0068667.g008
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and Bax [40], while we found the ectopic expression of RPL37 in
human osteosarcoma cells led to the selective upregulation of p21
and Puma but not Mdm2, Noxa or Bax. Furthermore, we found
that only RPS15 and RPS20 have the ability to upregulate
additional p53 targets, namely Mdm2 and miR-34a mRNAs. It
remains to be seen if these RPs can be found at the promoters of
these upregulated p53 targets, as was recently shown for RPL11
and various p53 targets following ActD treatment [41]. Since
ChIP experiments rely on antibodies that can efficiently immu-
noprecipitate the protein of interest, and such antibodies are
presently lacking for these RPs, those experiments will need to wait
for the development of the appropriate reagents. RPS15 and
RPS20 were also the only RPs that could co-immunoprecipitate
with MdmX and downregulate MdmX protein levels, while
RPL37 could downregulate both MdmX mRNA and protein
levels without physically interacting with the MdmX protein. It is
possible that RPS15 and RPS20 may function like RPL11 and
regulate MdmX protein levels by enhancing Mdm2-mediated
degradation [15], while RPL37 may use a mRNA-based
mechanism to regulate MdmX levels. As these differences are
explored in future studies, it is likely the model of segregating RPs
into effectors versus detectors may need to be modified.
Supporting Information
Figure S1 RPL37, RPS15, and RPS20 interact with
Mdm2. (a-c) U2OS cells were transfected with Flag-Mdm2
(1.2 mg), Myc-RP (1.2 mg), or both. (GFP was added as a control
for transfection efficiency.) Cells were then lysed and subjected to
immunoprecipitation and immunoblotting (IP) with the indicated
antibodies as described in Materials S1.
(TIF)
Figure S2 RPL37, RPS15, and RPS20 interact with the
central region of Mdm2. (a) H1299 cells were transfected with
Myc-RPL37 (1.2 mg), Flag-Mdm2 full length (1.2 mg), Flag-Mdm2
truncation 1–220 (0.1 mg), Flag-Mdm2 deletion 222–272 (1.2 mg),
Flag-Mdm2 deletion 222–340 (1.1 mg), Flag-Mdm2 deletion 340–
437 (0.1 mg), and Flag-Mdm2 truncation 436–482 (0.5 mg). (b)
H1299 cells were transfected with Myc-RPS15 (1.2 mg), Flag-
Mdm2 full length (1.2 mg), Flag-Mdm2 truncation 1–154 (1.2 mg),
Flag-Mdm2 truncation 1–220 (0.1 mg), Flag-Mdm2 deletion 222–
272 (1.2 mg), Flag-Mdm2 deletion 222–340 (0.5 mg), Flag-Mdm2
deletion 340–437 (0.25 mg), and Flag-Mdm2 truncation 436–482
(0.25 mg). (c) H1299 cells were transfected with Myc-RPS20
(1.2 mg), Flag-Mdm2 full length (1.2 mg), Flag-Mdm2 truncation
1–154 (0.04 mg), Flag-Mdm2 truncation 1–220 (0.02 mg), Flag-
Mdm2 deletion 222–272 (1.95 mg), Flag-Mdm2 deletion 222–340
(1.0 mg), Flag-Mdm2 deletion 340–437 (0.1 mg), and Flag-Mdm2
truncation 436–482 (0.3 mg). (d) H1299 cells were transfected with
Myc-RPS20 (1.2 mg) and equal amounts of each Flag-Mdm2
construct (1.2 mg of full length, truncation 1–220, deletion 222–
340, deletion 340–437, truncation 438–483). (e) H1299 cells were
transfected with Myc-RPS20 (1.2 mg), Flag-Mdm2 full length
(1.2 mg), Flag-Mdm2 truncation 1–220 (0.3 mg), Flag-Mdm2
deletion 222–340 (0.9 mg), Flag-Mdm2 deletion 340–437
(0.3 mg), and Flag-Mdm2 truncation 436–482 (0.4 mg). For all
transfections, Myc-RPs were immunoprecipitated with a-Myc and
co-immunoprecipitation of each RP and each Mdm2 construct
was assayed by immunoblotting with a-Myc and a-Flag. In panels
(b) – (d), inputs and IPs were run on separate gels.
(TIF)
Figure S3 RPL37, RPS15, and RPS20 stabilize Mdm2.
H1299 cells were grown on coverslips in 35 mM tissue culture
plates and transfected with Flag-Mdm2 (1.2 mg), Myc-RP (1.2 mg),
or both. Immunofluorescent staining was carried out as described.
(TIF)
Figure S4 RPL37, RPS15, and RPS20 do not upregulate
mRNA levels of Ccng1, Bax, Noxa, or Tigar. U2OS cells
were seeded in 60 mM tissue culture plates and transfected with
increasing amounts of Myc-RP (0–7.5 mg). Relative expression of
each gene was determined in triplicate by quantitative RT-PCR
and normalized to GAPDH. A representative experiment is
plotted, and significant changes in mRNA levels were calculated
using student’s t-test (* = p,0.05; ** = p,0.01; n .3).
(TIF)
Table S1 siRNA sequences. The sequences for the siRNAs
used are provided.
(TIF)
Table S2 qRT-PCR sequences. The primer sequences for
the qRT-PCR reactions performed are provided.
(TIF)
Materials S1 Description of immunofluorescent mi-
croscopy methods. The materials and methods employed for
the immunofluorescent images shown in Figure S1 are described.
(DOC)
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